TREX1 acts in degrading damaged DNA from drug-treated tumor cells

DNA Repair

Volumn 8, Issue 10, 2009, Pages 1179-1189

  Wang, Chuan Jen ^a   Lam, Wing ^a   Bussom, Scott ^a   Chang, Hua Mei ^a   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Camptothecin; DNA degradation; Dying cells; TREX1

Indexed keywords

ARSENIC TRIOXIDE; CAMPTOTHECIN; CISPLATIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; EXONUCLEASE; GEMCITABINE; HYDROGEN PEROXIDE; OXALIPLATIN; PROTEIN TREX1; TROXACITABINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL DEATH; CLONOGENESIS; CONTROLLED STUDY; DNA DAMAGE; DNA DEGRADATION; DNA REPAIR; DRUG EFFECT; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CELL LINE, TUMOR; DNA; DNA DAMAGE; DNA REPAIR; EXODEOXYRIBONUCLEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PHOSPHOPROTEINS; PROTEIN TRANSPORT; RNA, MESSENGER;

MAMMALIA;

EID: 70149107812     PISSN: 15687864     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dnarep.2009.06.006     Document Type: Article

References (56)

1. Lindahl T., Gally J.A., and Edelman G.M. Properties of deoxyribonuclease 3 from mammalian tissues. J. Biol. Chem. 244 (1969) 5014-5019
2. Hoss M., Robins P., Naven T.J., Pappin D.J., Sgouros J., and Lindahl T. A human DNA editing enzyme homologous to the Escherichia coli DnaQ/MutD protein. EMBO J. 18 (1999) 3868-3875
3. Mazur D.J., and Perrino F.W. Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3′ → 5′ exonucleases. J. Biol. Chem. 274 (1999) 19655-19660
4. Mazur D.J., and Perrino F.W. Excision of 3′ termini by the Trex1 and TREX2 3′ → 5′ exonucleases, characterization of the recombinant proteins. J. Biol. Chem. 276 (2001) 17022-17029
5. Perrino F.W., Miller H., and EaleyF K.A. Identification of a 3′ → 5′-exonuclease that removes cytosine arabinoside monophosphate from 3′ termini of DNA. J. Biol. Chem. 269 (1994) 16357-16363
6. de Silva U., Choudhury S., Bailey S.L., Harvey S., Perrino F.W., and Hollis T. The crystal structure of TREX1 explains the 3′ nucleotide specificity and reveals a polyproline II helix for protein partnering. J. Biol. Chem. 282 (2007) 10537-10543
7. Perrino F.W., Harvey S., McMillin S., and Hollis T. The human TREX2 3′ → 5′-exonuclease structure suggests a mechanism for efficient nonprocessive DNA catalysis. J. Biol. Chem. 280 (2005) 15212-15218
8. Brucet M., Querol-Audi J., Serra M., Ramirez-Espain X., Bertlik K., Ruiz L., Lloberas J., Macias M.J., Fita I., and Celada A. Structure of the dimeric exonuclease TREX1 in complex with DNA displays a proline-rich binding site for WW Domains. J. Biol. Chem. 282 (2007) 14547-14557
9. Shevelev I.V., Ramadan K., and Hubscher U. The TREX2 3′ → 5′ exonuclease physically interacts with DNA polymerase delta and increases its accuracy. Sci. World J. 2 (2002) 275-281
10. Morita M., Stamp G., Robins P., Dulic A., Rosewell I., Hrivnak G., Daly G., Lindahl T., and Barnes D.E. Gene-targeted mice lacking the Trex1 (DNase III) 3′ → 5′ DNA exonuclease develop inflammatory myocarditis. Mol. Cell. Biol. 24 (2004) 6719-6727
11. Crow Y.J., Hayward B.E., Parmar R., Robins P., Leitch A., Ali M., Black D.N., van Bokhoven H., Brunner H.G., Hamel B.C., Corry P.C., Cowan F.M., Frints S.G., Klepper J., Livingston J.H., Lynch S.A., Massey R.F., Meritet J.F., Michaud J.L., Ponsot G., Voit T., Lebon P., Bonthron D.T., Jackson A.P., Barnes D.E., and Lindahl T. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat. Genet. 38 (2006) 917-920
12. Rice G., Patrick T., Parmar R., Taylor C.F., Aeby A., Aicardi J., Artuch R., Montalto S.A., Bacino C.A., Barroso B., Baxter P., Benko W.S., Bergmann C., Bertini E., Biancheri R., Blair E.M., Blau N., Bonthron D.T., Briggs T., Brueton L.A., Brunner H.G., Burke C.J., Carr I.M., Carvalho D.R., Chandler K.E., Christen H.J., Corry P.C., Cowan F.M., Cox H., D'Arrigo S., Dean J., De Laet C., De Praeter C., Dery C., Ferrie C.D., Flintoff K., Frints S.G., Garcia-Cazorla A., Gener B., Goizet C., Goutieres F., Green A.J., Guet A., Hamel B.C., Hayward B.E., Heiberg A., Hennekam R.C., Husson M., Jackson A.P., Jayatunga R., Jiang Y.H., Kant S.G., Kao A., King M.D., Kingston H.M., Klepper J., van der Knaap M.S., Kornberg A.J., Kotzot D., Kratzer W., Lacombe D., Lagae L., Landrieu P.G., Lanzi G., Leitch A., Lim M.J., Livingston J.H., Lourenco C.M., Lyall E.G., Lynch S.A., Lyons M.J., Marom D., McClure J.P., McWilliam R., Melancon S.B., Mewasingh L.D., Moutard M.L., Nischal K.K., Ostergaard J.R., Prendiville J., Rasmussen M., Rogers R.C., Roland D., Rosser E.M., Rostasy K., Roubertie A., Sanchis A., Schiffmann R., Scholl-Burgi S., Seal S., Shalev S.A., Corcoles C.S., Sinha G.P., Soler D., Spiegel R., Stephenson J.B., Tacke U., Tan T.Y., Till M., Tolmie J.L., Tomlin P., Vagnarelli F., Valente E.M., Van Coster R.N., Van der Aa N., Vanderver A., Vles J.S., Voit T., Wassmer E., Weschke B., Whiteford M.L., Willemsen M.A., Zankl A., Zuberi S.M., Orcesi S., Fazzi E., Lebon P., and Crow Y.J. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am. J. Hum. Genet. 81 (2007) 713-725
13. Stephenson J.B. Aicardi-Goutieres syndrome (AGS). Eur. J. Paediatr. Neurol. 12 (2008) 355-358
14. Richards A., van den Maagdenberg A.M., Jen J.C., Kavanagh D., Bertram P., Spitzer D., Liszewski M.K., Barilla-Labarca M.L., Terwindt G.M., Kasai Y., McLellan M., Grand M.G., Vanmolkot K.R., de Vries B., Wan J., Kane M.J., Mamsa H., Schafer R., Stam A.H., Haan J., de Jong P.T., Storimans C.W., van Schooneveld M.J., Oosterhuis J.A., Gschwendter A., Dichgans M., Kotschet K.E., Hodgkinson S., Hardy T.A., Delatycki M.B., Hajj-Ali R.A., Kothari P.H., Nelson S.F., Frants R.R., Baloh R.W., Ferrari M.D., and Atkinson J.P. C-terminal truncations in human 3′-5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat. Genet. 39 (2007) 1068-1070
15. Stam A.H., van den Maagdenberg A.M., Haan J., Terwindt G.M., and Ferrari M.D. Genetics of migraine: an update with special attention to genetic comorbidity. Curr. Opin. Neurol. 21 (2008) 288-293
16. Lee-Kirsch M.A., Gong M., Chowdhury D., Senenko L., Engel K., Lee Y.A., de Silva U., Bailey S.L., Witte T., Vyse T.J., Kere J., Pfeiffer C., Harvey S., Wong A., Koskenmies S., Hummel O., Rohde K., Schmidt R.E., Dominiczak A.F., Gahr M., Hollis T., Perrino F.W., Lieberman J., and Hubner N. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat. Genet. 39 (2007) 1065-1067
17. Rice G., Newman W.G., Dean J., Patrick T., Parmar R., Flintoff K., Robins P., Harvey S., Hollis T., O'Hara A., Herrick A.L., Bowden A.P., Perrino F.W., Lindahl T., Barnes D.E., and Crow Y.J. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am. J. Hum. Genet. 80 (2007) 811-815
18. Lee-Kirsch M.A., Gong M., Schulz H., Ruschendorf F., Stein A., Pfeiffer C., Ballarini A., Gahr M., Hubner N., and Linne M. Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am. J. Hum. Genet. 79 (2006) 731-737
19. Lee-Kirsch M.A., Chowdhury D., Harvey S., Gong M., Senenko L., Engel K., Pfeiffer C., Hollis T., Gahr M., Perrino F.W., Lieberman J., and Hubner N. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J. Mol. Med. 85 (2007) 531-537
20. Lehtinen D.A., Harvey S., Mulcahy M.J., Hollis T., and Perrino F.W. The TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease. J. Biol. Chem. 283 (2008) 31649-31656
21. Yang Y.G., Lindahl T., and Barnes D.E. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 131 (2007) 873-886
22. Coscoy L., and Raulet D.H. DNA mismanagement leads to immune system oversight. Cell 131 (2007) 836-838
23. Brooks P.J., Cheng T.F., and Cooper L. Do all of the neurologic diseases in patients with DNA repair gene mutations result from the accumulation of DNA damage?. DNA Rep. (Amst.) 7 (2008) 834-848
24. O'Driscoll M. TREX1 DNA exonuclease deficiency, accumulation of single stranded DNA and complex human genetic disorders. DNA Rep. (Amst.) 7 (2008) 997-1003
25. Stetson D.B., Ko J.S., Heidmann T., and Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134 (2008) 587-598
26. Chowdhury D., Beresford P.J., Zhu P., Zhang D., Sung J.S., Demple B., Perrino F.W., and Lieberman J. The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death. Mol. Cell 23 (2006) 133-142
27. Chowdhury D., and Lieberman J. Death by a thousand cuts: granzyme pathways of programmed cell death. Annu. Rev. Immunol. 26 (2008) 389-420
28. Lam W., Chen C., Ruan S., Leung C.H., and Cheng Y.C. Expression of deoxynucleotide carrier is not associated with the mitochondrial DNA depletion caused by anti-HIV dideoxynucleoside analogs and mitochondrial dNTP uptake. Mol. Pharmacol. 67 (2005) 408-416
29. Chou K.M., and Cheng Y.C. The exonuclease activity of human apurinic/apyrimidinic endonuclease (APE1). Biochemical properties and inhibition by the natural dinucleotide Gp4G. J. Biol. Chem. 278 (2003) 18289-18296
30. Nutter L.M., Grill S.P., Li J.S., Tan R.S., and Cheng Y.C. Induction of virus enzymes by phorbol esters and n-butyrate in Epstein-Barr virus genome-carrying Raji cells. Cancer Res. 47 (1987) 4407-4412
31. Gao W., Lam W., Zhong S., Kaczmarek C., Baker D.C., and Cheng Y.C. Novel mode of action of tylophorine analogs as antitumor compounds. Cancer Res. 64 (2004) 678-688
32. Nutter L.M., Grill S.P., and Cheng Y.C. The sources of thymidine nucleotides for virus DNA synthesis in herpes simplex virus type 2-infected cells. J. Biol. Chem. 260 (1985) 13272-13275
33. Mazur D.J., and Perrino F.W. Structure and expression of the TREX1 and TREX2 3′ → 5′ exonuclease genes. J. Biol. Chem. 276 (2001) 14718-14727
34. Beidler D.R., and Cheng Y.C. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol. Pharmacol. 47 (1995) 907-914
35. Deptala A., Li X., Bedner E., Cheng W., Traganos F., and Darzynkiewicz Z. Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin. Int. J. Oncol. 15 (1999) 861-871
36. Althaus F.R., Kleczkowska H.E., Malanga M., Muntener C.R., Pleschke J.M., Ebner M., and AuerF B. Poly ADP-ribosylation: a DNA break signal mechanism. Mol. Cell. Biochem. 193 (1999) 5-11
37. Simizu S., Takada M., Umezawa K., and Imoto M. Requirement of caspase-3(-like) protease-mediated hydrogen peroxide production for apoptosis induced by various anticancer drugs. J. Biol. Chem. 273 (1998) 26900-26907
38. Tramontano F., Di Meglio S., and Quesada P. Co-localization of poly(ADPR)polymerase 1 (PARP-1) poly(ADPR)polymerase 2 (PARP-2) and related proteins in rat testis nuclear matrix defined by chemical cross-linking. J. Cell. Biochem. 94 (2005) 58-66
39. Laurincik J., and Maddox-Hyttel P. Nucleolar remodeling in nuclear transfer embryos. Adv. Exp. Med. Biol. 591 (2007) 84-92
40. Anachkova B., Djeliova V., and Russev G. Nuclear matrix support of DNA replication. J. Cell. Biochem. 96 (2005) 951-961
41. Stein G.S., Zaidi S.K., Braastad C.D., Montecino M., van Wijnen A.J., Choi J.Y., Stein J.L., Lian J.B., and Javed A. Functional architecture of the nucleus: organizing the regulatory machinery for gene expression, replication and repair. Trends Cell Biol. 13 (2003) 584-592
42. Zaidi S.K., Young D.W., Choi J.Y., Pratap J., Javed A., Montecino M., Stein J.L., van Wijnen A.J., Lian J.B., and Stein G.S. The dynamic organization of gene-regulatory machinery in nuclear microenvironments. EMBO Rep. 6 (2005) 128-133
43. Mummenbrauer T., Janus F., Muller B., Wiesmuller L., Deppert W., and Grosse F. p53 Protein exhibits 3′-to-5′ exonuclease activity. Cell 85 (1996) 1089-1099
44. Chen M.J., Dumitrache L.C., Wangsa D., Ma S.M., Padilla-Nash H., Ried T., and Hasty P. Cisplatin depletes TREX2 and causes Robertsonian translocations as seen in TREX2 knockout cells. Cancer Res. 67 (2007) 9077-9083
45. Degols G., Eldin P., and Mechti N. ISG20, an actor of the innate immune response. Biochimie 89 (2007) 831-835
46. Hsiang Y.H., Hertzberg R., Hecht S., and Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260 (1985) 14873-14878
47. Li T.K., and Liu L.F. Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 53-77
48. Nagata S., Nagase H., Kawane K., Mukae N., and Fukuyama H. Degradation of chromosomal DNA during apoptosis. Cell Death Differ. 10 (2003) 108-116
49. Hellweg C.E., Arenz A., Bogner S., Schmitz C., and Baumstark-Khan C. Activation of nuclear factor kappa B by different agents: influence of culture conditions in a cell-based assay. Ann. N.Y. Acad. Sci. 1091 (2006) 191-204
50. Fan J., Zhan M., Shen J., Martindale J.L., Yang X., Kawai T., and Gorospe M. En masse nascent transcription analysis to elucidate regulatory transcription factors. Nucleic Acids Res. 34 (2006) 1492-1500
51. Krug A. Nucleic acid recognition receptors in autoimmunity. Handb. Exp. Pharmacol. (2008) 129-151
52. Bhoj V.G., and Chen Z.J. Linking retroelements to autoimmunity. Cell 134 (2008) 569-571
53. He L., Kim B.Y., Kim K.A., Kwon O., Kim S.O., Bae E.Y., Lee M.S., Kim M.S., Jung M., Moon A., Bae K., and Ahn J.S. NF-kappaB inhibition enhances caspase-3 degradation of Akt1 and apoptosis in response to camptothecin. Cell. Signal. 19 (2007) 1713-1721
54. Gaipl U.S., Munoz L.E., Grossmayer G., Lauber K., Franz S., Sarter K., Voll R.E., Winkler T., Kuhn A., Kalden J., Kern P., and Herrmann M. Clearance deficiency and systemic lupus erythematosus (SLE). J. Autoimmun. 28 (2007) 114-121
55. Tanaka M., and Miyake Y. Apoptotic cell clearance and autoimmune disorder. Curr. Med. Chem. 14 (2007) 2892-2897
56. Gaipl U.S., Voll R.E., Sheriff A., Franz S., Kalden J.R., and Herrmann M. Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun. Rev. 4 (2005) 189-194